Last reviewed · How we verify
Companion Tablet — Competitive Intelligence Brief
phase 3
Parasitology/Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Companion Tablet (Companion Tablet) — Jiangsu Institute of Parasitic Diseases. Companion Tablet is an antiparasitic agent developed for treatment of parasitic infections.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Companion Tablet TARGET | Companion Tablet | Jiangsu Institute of Parasitic Diseases | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Companion Tablet CI watch — RSS
- Companion Tablet CI watch — Atom
- Companion Tablet CI watch — JSON
- Companion Tablet alone — RSS
Cite this brief
Drug Landscape (2026). Companion Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/companion-tablet. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab